 |
| 03-May-13 | Initiated |
UBS |
Buy |
$61 |
|
| 03-Apr-13 | Downgrade |
Cantor Fitzgerald |
Hold → Sell |
$38 → $40 |
|
| 06-Feb-13 | Initiated |
Aegis Capital |
Hold |
$45 |
|
| 24-Jan-13 | Upgrade |
Cantor Fitzgerald |
Sell → Hold |
$37 → $38 |
|
| 04-Jan-13 | Resumed |
Robert W. Baird |
Neutral |
$46 |
|
| 09-Nov-12 | Initiated |
Mizuho |
Neutral |
$44 |
|
| 25-Oct-12 | Initiated |
Cantor Fitzgerald |
Sell |
$37 |
|
| 04-Apr-12 | Reiterated |
Oppenheimer |
Outperform |
$45 → $49 |
|
| 20-Oct-11 | Reiterated |
Oppenheimer |
Outperform |
$44 → $46 |
|
| 20-Oct-11 | Reiterated |
Needham |
Buy |
$39 → $42 |
|
| 15-Jul-11 | Reiterated |
Oppenheimer |
Outperform |
$37 → $44 |
|
| 20-Apr-11 | Upgrade |
Oppenheimer |
Perform → Outperform |
$37 |
|
| 18-Apr-11 | Reiterated |
Wedbush |
Outperform |
$32 → $40 |
|
| 15-Apr-11 | Reiterated |
RBC Capital Mkts |
Outperform |
$33 → $36 |
|
| 06-Apr-11 | Reiterated |
ThinkEquity |
Hold |
$20 → $30 |
|
| 05-Apr-11 | Upgrade |
Wedbush |
Neutral → Outperform |
$25 → $32 |
|
| 05-Apr-11 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$22 → $35 |
|
| 14-Apr-10 | Reiterated |
Wedbush |
Neutral |
$20 → $25 |
|
| 01-Apr-10 | Reiterated |
RBC Capital Mkts |
Outperform |
$24 → $26 |
|
| 03-Dec-09 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$21 → $24 |
|
|
|
| 16-May-13 03:25PM | A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical Sectors Wall Street Transcript |
| 01:30PM | Pipeline Progress at Gilead Zacks |
| 09:57AM | Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals at Seeking Alpha |
| 15-May-13 05:19PM | Cubist bid for Optimer before sale process began-sources at Reuters |
| 04:50PM | Cempra/Toyama Ink Deal Zacks |
| 04:08PM | Cubist bid almost $1 billion for Optimer before sale process: sources at Reuters |
| 03:47PM | Cubist bid almost $1 bln for Optimer before sale process-sources at Reuters |
| 11:40AM | Synergy Pharma Posts Wider Loss Zacks |
| 10:08AM | Is AstraZeneca Gearing Up for a Shopping Spree? at Motley Fool |
| 09:30AM | Wider-Than-Expected Loss at Athersys Zacks |
| 14-May-13 12:13PM | Celgene Attains 52-Week High Zacks |
| 10:23AM | Markman Hearing A Likely Clearing Event For Cubist - Decision Any Day at Seeking Alpha |
| 13-May-13 06:27PM | Trius Therapeutics: New, Positive Dimension For Investment Outlook at Seeking Alpha |
| 05:40PM | Setback for Endo Health on Opana ER Zacks |
| 04:53PM | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says theflyonthewall.com |
| 04:11PM | AstraZeneca, Cubist, Astellas Said to Make Bids for Optimer at Bloomberg |
| 08:41AM | Narrower-than-Expected Loss at MannKind Zacks |
| 11-May-13 01:04PM | CUBIST PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 10-May-13 12:27PM | 4 GARP Growers to Buy This Summer at TheStreet |
| 11:40AM | Wider-than-Expected Loss at Optimer Zacks |
| 09:10AM | The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals Zacks |
| 09-May-13 03:23PM | Good News for Cubist Pharmaceuticals Zacks |
| 08-May-13 05:55PM | Earnings Beat at Endo Health, Sales Slip Zacks |
| 05:24PM | Cubist to Present at Bank of America Merrill Lynch 2013 Healthcare Conference Business Wire |
| 07-May-13 11:55PM | 3 Healthcare Stock Stories For Tuesday Investment Wellness at Wall St. Cheat Sheet |
| 03:30PM | Positive Data on Forest Combo Drug Zacks |
| 01:50PM | Cubist antibiotic regimen gets fast-track review AP |
| 08:45AM | Alnylam Narrows Loss, Sales Fall Zacks |
| 08:34AM | InPlay: Cubist Pharma: FDA grants Fast Track designation for Cubist's late-stage antibiotic candidate Briefing.com |
| 08:30AM | FDA Grants Fast Track Designation for Cubists Late-Stage Antibiotic Candidate Business Wire |
| 01:48AM | CUBIST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 06-May-13 06:07PM | Alnylam takes smaller 1Q loss on lower costs AP |
| 12:20PM | Teva Beats on Earnings, Revenues Zacks |
| 03-May-13 12:43PM | On The Fly: Analyst Initiation Summary at theflyonthewall.com |
| 11:16AM | Wall Street Transcript Interview with Dr. Jason Kantor, Research Analyst at Credit Suisse Group: High Success Rates and Significant M&A in the Antibody Space Wall Street Transcript |
| 09:17AM | New Stock Coverage: Put Fresh Money to Work in Fossil at Minyanville |
| 03:20AM | Coverage initiated on Cubist Pharma by UBS Briefing.com |
| 30-Apr-13 06:00AM | Cramer's Top Stock Picks: PPG ETN CBST NFLX at TheStreet |
| 29-Apr-13 08:20PM | Cramer's 'Mad Money' Recap: Dazed and Confused Markets at TheStreet |
| 06:45PM | [video] Cubist Pharma CEO Talks New Lineup at CNBC |
| 11:00AM | FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market: A Wall Street Transcript Interview with Brian Skorney, Senior Analyst at Robert W. Baird & Co. Wall Street Transcript |
| 09:04AM | Wells Fargo Executive VP Sells More Than 14K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet |
| 23-Apr-13 06:52PM | A New Cure for Painkiller Constipation at Motley Fool |
| 04:10PM | Sucampo Wins Approval for Expanded Use of Amitiza in U.S. at Bloomberg |
| 07:33AM | Who's Fighting Superbugs? Not Big Pharma at CNBC |
| 07:33AM | Big Pharma Exit: Who's Fighting the Superbugs? at CNBC |
| 22-Apr-13 03:21PM | Big Pharma Exit: Who's Fighting the Superbugs? at CNBC |
| 09:24AM | Jump On Board With These 2 Companies at Seeking Alpha |
| 19-Apr-13 11:32AM | Boston Is Locked Down With City Frozen From Tufts to Trains at Bloomberg |
| 08:50AM | 1Q Earnings Beat at Cubist Pharma Zacks |
| 18-Apr-13 08:30PM | Cubist Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 05:46PM | Cubist Pharmaceuticals Earnings: Heres Why Investors are Selling Shares Now at Wall St. Cheat Sheet |
| 05:17PM | Cubist Pharma 1Q income falls after acquisition AP |
| 04:02PM | InPlay: Cubist Pharma misses by $0.16, misses on revs Briefing.com |
| 04:00PM | Cubist Pharmaceuticals Reports First Quarter 2013 Financial Results Business Wire |
| 09:15AM | CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online |
| 07:07AM | Q1 2013 Cubist Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN |
| 17-Apr-13 11:59PM | Drug pipeline for worst superbugs 'on life support' -U.S. report at Reuters |
| 16-Apr-13 10:50AM | Will Cubist Pharma Beat Earnings? Zacks |
| 11-Apr-13 08:30AM | Cubist to Announce First Quarter 2013 Financial Results on Thursday, April 18th, 2013 Business Wire |
| 09-Apr-13 02:00PM | Cubist Pharmaceuticals and the New England Patriots Radio Network Honor Lynn, Massachusetts Biology Teacher Business Wire |
| 01:02PM | Buying Into Cubist's Art Against Resistant Bacteria at Forbes |
| 08-Apr-13 11:17AM | Biotech Madness! at Motley Fool |
| 03-Apr-13 01:54PM | Delhaize Group Gets a Thumbs Down and 4 More Analyst Downgrades to Know About at Wall St. Cheat Sheet |
| 11:51AM | Cubist named as possible suitor for Optimer at bizjournals.com |
| 02-Apr-13 11:59PM | Cubist Pharma downgraded by Cantor Fitzgerald Briefing.com |
| 05:14PM | Is This Really Big Pharma's Next Acquisition? at Motley Fool |
| 05:14PM | 1 Biotech's Unexpected Bidding War at Motley Fool |
| 04:25PM | Optimer Said to Draw Takeover Interest From Glaxo at Bloomberg |
| 04:10PM | Cubist Rises On Unusually High Volume (CBST) at TheStreet |
| 02:30PM | Optimer shares rise after report names Glaxo, Cubist as potential buyers at Reuters |
| 02:29PM | UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers at Reuters |
| 09:39AM | Optimer Said to Draw Takeover Interest From Glaxo, Astellas at Bloomberg |
| 09:36AM | Optimer draws interest from Cubist, AstraZeneca, Glaxo, Bloomberg says at theflyonthewall.com |
| 01-Apr-13 11:45AM | David & Goliath: Small Biotechs Wage a Big Fight Against the Superbug at Minyanville |
| 21-Mar-13 04:42PM | Trius Therapeutics Is A Strong Investment Short And Long Term at Seeking Alpha |
| 18-Mar-13 12:04PM | New Product Development and Pipelines in Smaller Medical Devices Companies: Less European Exposure Results in More Limited Exposure to Downside Risk in Those Troubled Countries Across the Atlantic Wall Street Transcript |
| 10:19AM | [$$] Two Top Stock Ideas in Antibiotics at Barrons.com |
| 08:54AM | Trius: Topline Data From Second Phase III Trial Of Tedizolid Is Imminent at Seeking Alpha |
| 15-Mar-13 03:24PM | 4 Healthcare Stock Stories for Friday Investment Wellness at Wall St. Cheat Sheet |
| 10:00AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 14-Mar-13 10:04PM | Profit From These Rapidly Growing Small Caps at Motley Fool |
| 11:26AM | Greenblatt And Gotham's Newest Holdings at Seeking Alpha |
| 12-Mar-13 05:21PM | CBST Gets Global Rights to Antibiotic Candidate Zacks |
| 11-Mar-13 01:51PM | CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri EDGAR Online |
| 01:39PM | Cubist gains rights to potential drug to treat UTIs, other infections at bizjournals.com |
| 09:33AM | InPlay: Cubist Pharma obtains remaining rights to ceftolozane from Astellas (ALPMY.PK) Briefing.com |
| 08:30AM | Cubist Obtains Remaining Rights to Ceftolozane from Astellas Business Wire |
| 08-Mar-13 09:51AM | Cramer: Boeing, Berkshire, and These 3 Stocks Are Buys Now at Wall St. Cheat Sheet |
| 06:38AM | Cramer's Lightning Round - Speculate On Cubist (3/7/13) at Seeking Alpha |
| 06:00AM | 'Mad Money' Lightning Round: Solar Capital Is a Winner at TheStreet |
| 07-Mar-13 06:42PM | Lightning Round: Solar Capital, Cubist Pharma & More at CNBC |
| 06:40PM | [video] Lightning Round at CNBC |
| 05-Mar-13 01:33PM | CFO Moves: Cubist Pharmaceuticals, Nomura, Crailar Technologies at The Wall Street Journal |
| 01:04PM | CUBIST PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 04-Mar-13 08:13PM | Cubist Names New CFO at Motley Fool |
| 02:28PM | Optimer Posts Wider Loss Zacks |
| 02:19PM | Cubist appoints former GE and Motorola exec as CFO at bizjournals.com |
| 12:21PM | Cubist Pharma names Michael Tomsicek as new CFO AP |
| 11:57AM | CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online |
|
|
| Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States. It provides CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also co-promotes DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD). In addition, its development products include Ceftolozane/tazobactam that is in Phase III clinical trials to treat complicated urinary tract infections and complicated intra-abdominal infections. Further, the company is developing ceftolozane/tazobactam for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Additionally, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain; and CB-625 that is in Phase I clinical studies to treat acute pain and various inflammatory conditions. In addition, the company’s pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| BONNEY MICHAEL W | Chief Executive Officer | May 16 | Sale | 47.88 | 2,400 | 114,902 | 161,518 | May 17 12:32 PM | | PEREZ ROBERT J | President & COO | May 16 | Sale | 47.88 | 1,500 | 71,814 | 35,945 | May 17 12:34 PM | | STEA GREGORY | SVP, Commercial Operations | May 16 | Sale | 47.88 | 268 | 12,831 | 14,189 | May 17 12:35 PM | | BATE KENNETH | Director | May 15 | Option Exercise | 11.89 | 2,500 | 29,725 | 8,339 | May 17 12:31 PM | | STEA GREGORY | SVP, Commercial Operations | May 15 | Option Exercise | 0.00 | 800 | 0 | 14,457 | May 17 12:35 PM | | PEREZ ROBERT J | President & COO | May 15 | Option Exercise | 0.00 | 3,125 | 0 | 37,445 | May 17 12:34 PM | | BONNEY MICHAEL W | Chief Executive Officer | May 15 | Option Exercise | 0.00 | 5,000 | 0 | 163,918 | May 17 12:32 PM | | BATE KENNETH | Director | May 15 | Sale | 48.41 | 2,500 | 121,025 | 5,839 | May 17 12:31 PM | | BONNEY MICHAEL W | Chief Executive Officer | May 15 | Sale | 48.41 | 2,979 | 144,227 | 158,918 | May 16 03:44 PM | | PEREZ ROBERT J | President & COO | May 15 | Sale | 48.41 | 1,490 | 72,138 | 34,320 | May 16 03:43 PM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | May 15 | Sale | 48.41 | 1,017 | 49,238 | 22,208 | May 16 03:45 PM | | STEA GREGORY | SVP, Commercial Operations | May 15 | Sale | 48.41 | 594 | 28,758 | 13,657 | May 16 03:46 PM | | STEA GREGORY | SVP, Commercial Operations | May 14 | Option Exercise | 0.00 | 1,800 | 0 | 14,251 | May 16 03:46 PM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | May 14 | Option Exercise | 0.00 | 2,500 | 0 | 23,225 | May 16 03:45 PM | | PEREZ ROBERT J | President & COO | May 14 | Option Exercise | 0.00 | 3,125 | 0 | 35,810 | May 16 03:43 PM | | BONNEY MICHAEL W | Chief Executive Officer | May 14 | Option Exercise | 0.00 | 6,250 | 0 | 161,897 | May 16 03:44 PM | | BONNEY MICHAEL W | Chief Executive Officer | May 14 | Sale | 49.18 | 3,753 | 184,569 | 155,647 | May 15 05:15 PM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | May 14 | Sale | 49.18 | 1,135 | 55,818 | 20,725 | May 15 05:16 PM | | STEA GREGORY | SVP, Commercial Operations | May 14 | Sale | 49.18 | 585 | 28,770 | 12,451 | May 15 05:28 PM | | PEREZ ROBERT J | President & COO | May 14 | Sale | 49.18 | 2,346 | 115,374 | 32,685 | May 15 05:27 PM | | TOMSICEK MICHAEL JOHN | SVP & Chief Financial Officer | May 14 | Sale | 49.18 | 488 | 23,999 | 1,203 | May 15 05:25 PM | | TOMSICEK MICHAEL JOHN | SVP & Chief Financial Officer | May 13 | Option Exercise | 0.00 | 1,500 | 0 | 1,691 | May 15 05:25 PM | | PEREZ ROBERT J | President & COO | May 13 | Option Exercise | 0.00 | 5,000 | 0 | 35,031 | May 15 05:27 PM | | STEA GREGORY | SVP, Commercial Operations | May 13 | Option Exercise | 0.00 | 1,800 | 0 | 13,036 | May 15 05:28 PM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | May 13 | Option Exercise | 0.00 | 3,500 | 0 | 21,860 | May 15 05:16 PM | | Hutson Nancy J | Director | Apr 26 | Option Exercise | 18.22 | 5,000 | 91,100 | 8,500 | Apr 26 02:35 PM | | Hutson Nancy J | Director | Apr 26 | Sale | 46.23 | 5,000 | 231,131 | 3,500 | Apr 26 02:35 PM | | PEREZ ROBERT J | President & COO | Apr 02 | Option Exercise | 10.35 | 15,000 | 155,250 | 45,031 | Apr 02 04:05 PM | | PEREZ ROBERT J | President & COO | Apr 02 | Sale | 47.98 | 15,000 | 719,700 | 30,031 | Apr 02 04:05 PM | | STEA GREGORY | SVP, Commercial Operations | Mar 08 | Option Exercise | 16.76 | 4,375 | 73,325 | 15,611 | Mar 08 03:17 PM | | STEA GREGORY | SVP, Commercial Operations | Mar 08 | Sale | 48.00 | 4,375 | 210,000 | 11,236 | Mar 08 03:17 PM | | BATE KENNETH | Director | Mar 06 | Option Exercise | 11.89 | 5,000 | 59,450 | 10,839 | Mar 07 04:43 PM | | BATE KENNETH | Director | Mar 06 | Sale | 47.50 | 5,000 | 237,500 | 5,839 | Mar 07 04:43 PM | | STEA GREGORY | SVP, Commercial Operations | Mar 05 | Option Exercise | 16.76 | 4,375 | 73,325 | 15,611 | Mar 05 04:59 PM | | STEA GREGORY | SVP, Commercial Operations | Mar 05 | Sale | 46.00 | 4,375 | 201,250 | 11,236 | Mar 05 04:59 PM | | STEA GREGORY | SVP, Commercial Operations | Mar 04 | Option Exercise | 16.76 | 4,375 | 73,325 | 15,611 | Mar 05 04:59 PM | | STEA GREGORY | SVP, Commercial Operations | Mar 04 | Sale | 44.00 | 4,375 | 192,504 | 11,236 | Mar 05 04:59 PM | | STEA GREGORY | SVP, Commercial Operations | Feb 28 | Option Exercise | 18.52 | 5,625 | 104,175 | 16,861 | Mar 01 01:47 PM | | STEA GREGORY | SVP, Commercial Operations | Feb 28 | Sale | 42.00 | 5,625 | 236,258 | 11,236 | Mar 01 01:47 PM | | BONNEY MICHAEL W | President & CEO | Feb 19 | Option Exercise | 0.00 | 9,500 | 0 | 152,000 | Feb 20 11:20 AM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | Feb 19 | Sale | 41.40 | 1,233 | 51,047 | 18,360 | Feb 20 11:43 AM | | LARANJEIRA CHARLES ANTHONY | SVP, Technical Operations | Feb 19 | Sale | 41.40 | 384 | 15,898 | 1,257 | Feb 20 11:45 AM | | PEREZ ROBERT J | President & COO | Feb 19 | Sale | 41.40 | 2,177 | 90,128 | 30,031 | Feb 20 11:47 AM | | STEA GREGORY | SVP, Commercial Operations | Feb 19 | Sale | 41.40 | 611 | 25,296 | 11,236 | Feb 20 11:48 AM | | STEA GREGORY | SVP, Commercial Operations | Feb 16 | Option Exercise | 0.00 | 1,600 | 0 | 11,847 | Feb 20 11:48 AM | | PEREZ ROBERT J | President & COO | Feb 16 | Option Exercise | 0.00 | 5,000 | 0 | 32,208 | Feb 20 11:47 AM | | MCGIRR DAVID W J | SVP & Chief Financial Officer | Feb 16 | Option Exercise | 0.00 | 1,500 | 0 | 18,700 | Feb 20 11:46 AM | | LARANJEIRA CHARLES ANTHONY | SVP, Technical Operations | Feb 16 | Option Exercise | 0.00 | 1,000 | 0 | 1,641 | Feb 20 11:45 AM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | Feb 16 | Option Exercise | 0.00 | 3,750 | 0 | 19,593 | Feb 20 11:43 AM | | BONNEY MICHAEL W | President & CEO | Jan 29 | Option Exercise | 8.23 | 65,100 | 535,773 | 207,600 | Jan 30 05:11 PM | | BONNEY MICHAEL W | President & CEO | Jan 29 | Sale | 42.85 | 65,100 | 2,789,372 | 142,500 | Jan 30 05:11 PM | | Hutson Nancy J | Director | Jan 28 | Option Exercise | 17.95 | 5,000 | 89,750 | 8,500 | Jan 30 05:09 PM | | BONNEY MICHAEL W | President & CEO | Jan 28 | Option Exercise | 8.23 | 40,352 | 332,097 | 182,852 | Jan 30 05:11 PM | | BONNEY MICHAEL W | President & CEO | Jan 28 | Sale | 43.09 | 40,352 | 1,738,913 | 142,500 | Jan 30 05:11 PM | | Hutson Nancy J | Director | Jan 28 | Sale | 43.27 | 5,000 | 216,340 | 3,500 | Jan 30 05:09 PM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | Jan 02 | Option Exercise | 18.69 | 15,000 | 280,350 | 30,843 | Jan 03 01:21 PM | | GILMAN STEVEN C | EVP & Chief Scientific Officer | Jan 02 | Sale | 42.98 | 15,000 | 644,745 | 15,843 | Jan 03 01:21 PM | | Hutson Nancy J | Director | Oct 26 | Option Exercise | 17.95 | 5,000 | 89,750 | 8,500 | Oct 30 09:17 AM | | Hutson Nancy J | Director | Oct 26 | Sale | 43.52 | 5,000 | 217,615 | 3,500 | Oct 30 09:17 AM | | Rosenberg Martin | Director | Oct 01 | Option Exercise | 22.71 | 10,000 | 227,100 | 14,658 | Oct 02 04:11 PM | | Rosenberg Martin | Director | Oct 01 | Sale | 47.75 | 10,000 | 477,475 | 4,658 | Oct 02 04:11 PM | | MCGIRR DAVID W J | SVP & Chief Financial Officer | Sep 21 | Option Exercise | 10.35 | 15,000 | 155,250 | 32,200 | Sep 24 03:17 PM | | MCGIRR DAVID W J | SVP & Chief Financial Officer | Sep 21 | Sale | 49.79 | 15,000 | 746,850 | 17,200 | Sep 24 03:17 PM | | MCGIRR DAVID W J | SVP & Chief Financial Officer | Aug 24 | Option Exercise | 10.35 | 20,000 | 207,000 | 37,200 | Aug 27 03:39 PM | | PEREZ ROBERT J | President & COO | Aug 24 | Option Exercise | 10.87 | 30,000 | 326,100 | 57,038 | Aug 27 03:40 PM | | SINGLETON J MATTHEW | Director | Aug 24 | Option Exercise | 10.09 | 2,500 | 25,225 | 6,125 | Aug 27 03:38 PM | | PEREZ ROBERT J | President & COO | Aug 24 | Sale | 45.97 | 30,000 | 1,379,178 | 27,038 | Aug 27 03:40 PM | | MCGIRR DAVID W J | SVP & Chief Financial Officer | Aug 24 | Sale | 45.69 | 20,000 | 913,870 | 17,200 | Aug 27 03:39 PM | | SINGLETON J MATTHEW | Director | Aug 24 | Sale | 45.52 | 2,500 | 113,800 | 3,625 | Aug 27 03:38 PM | | STEA GREGORY | SVP, Commercial Operations | Aug 07 | Option Exercise | 18.52 | 7,500 | 138,900 | 17,747 | Aug 09 02:33 PM | | STEA GREGORY | SVP, Commercial Operations | Aug 07 | Sale | 44.00 | 7,500 | 330,000 | 10,247 | Aug 09 02:33 PM | | STEA GREGORY | SVP, Commercial Operations | Aug 01 | Sale | 42.90 | 136 | 5,834 | 0 | May 17 12:35 PM | | STEA GREGORY | SVP, Commercial Operations | Jul 26 | Option Exercise | 18.52 | 7,500 | 138,900 | 17,747 | Jul 26 04:12 PM | | STEA GREGORY | SVP, Commercial Operations | Jul 26 | Sale | 42.00 | 7,500 | 315,000 | 10,247 | Jul 26 04:12 PM | | CORRIGAN MARK | Director | Jul 24 | Option Exercise | 17.78 | 10,000 | 177,800 | 13,156 | Jul 26 04:11 PM | | CORRIGAN MARK | Director | Jul 24 | Sale | 41.01 | 10,000 | 410,075 | 3,156 | Jul 26 04:11 PM | | Rosenberg Martin | Director | Jul 02 | Option Exercise | 22.50 | 10,000 | 225,025 | 14,658 | Jul 03 12:25 PM | | Rosenberg Martin | Director | Jul 02 | Sale | 37.88 | 10,000 | 378,756 | 4,658 | Jul 03 12:25 PM | | STEA GREGORY | SVP, Commercial Operations | May 30 | Option Exercise | 18.45 | 9,000 | 166,050 | 17,693 | May 31 05:18 PM | | STEA GREGORY | SVP, Commercial Operations | May 30 | Sale | 40.05 | 9,000 | 360,450 | 8,693 | May 31 05:18 PM |
|
|
|
|
|
|
